MyFinsight
Home
Blog
About
Available-for-sale marketable
securities
$167,621K
(5.93%↑ Y/Y)
Cash and cash
equivalents
$31,806K
(-40.48%↓ Y/Y)
Prepaid expenses and
other current assets
$7,115K
(168.49%↑ Y/Y)
Total current assets
$206,542K
(-3.63%↓ Y/Y)
Operating lease
right-of-use assets
$7,848K
(55.44%↑ Y/Y)
Other non-current
assets
$3,444K
(-15.03%↓ Y/Y)
Property and equipment,
net
$1,326K
(-38.67%↓ Y/Y)
Restricted cash
$551K
(0.00%↑ Y/Y)
Finance lease
right-of-use assets
$112K
(-69.40%↓ Y/Y)
Total assets
$219,823K
(-2.95%↓ Y/Y)
Total liabilities and
stockholders' equity
$219,823K
(-2.95%↓ Y/Y)
Total stockholders'
equity
$165,549K
(-10.21%↓ Y/Y)
Total liabilities
$54,274K
(28.82%↑ Y/Y)
Accumulated deficit
-$502,874K
(-43.58%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$142K
(-610.00%↓ Y/Y)
Additional paid-in capital
$668,564K
(25.05%↑ Y/Y)
Term loan
$24,883K
Total current
liabilities
$22,802K
(-42.69%↓ Y/Y)
Operating lease
liabilities, net of...
$6,589K
(184.50%↑ Y/Y)
Common stock, 0.00001
par value...
$1K
Other accrued
expenses and current...
$9,112K
(-39.56%↓ Y/Y)
Accrued compensation
$5,481K
(10.26%↑ Y/Y)
Accrued license expense
- related party
$3,750K
(-40.00%↓ Y/Y)
Accounts payable
$2,933K
(-70.42%↓ Y/Y)
Operating lease
liabilities, short-term...
$1,400K
(-57.37%↓ Y/Y)
Finance lease
liabilities
$126K
(-56.85%↓ Y/Y)
Back
Back
Balance Sheet
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)
source: myfinsight.com